Nordicus Partners Corporation (NORD)
Nasdaq · Industrials · Biotechnology
$3.73−9.02%as of Nov 5, 2026, 1:49 AM ET
- Market cap
- $72.5M
- 52-week range
- $1.48 – $5.15
- 52-week change
- −18.00%
- EPS (trailing)
- −$0.28
Fiscal year to Mar 2026
- Net income
- −$4.0M
- Diluted EPS
- −$0.22
- Free cash flow
- −$4.3M
From the company’s annual report on SEC EDGAR.
About Nordicus Partners Corporation
Nordicus Partners Corporation, a biotech company specializing in developing breakthrough therapeutics for diseases with unmet medical needs in the United States. It develops medicines supporting oral health. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California.
Headquarters: Beverly Hills, United States · nordicuspartners.com